Aghazadeh Behzad 4
4 · IMMUNOMEDICS INC · Filed Nov 20, 2019
Insider Transaction Report
Form 4
IMMUNOMEDICS INCIMMU
Aghazadeh Behzad
Director10% OwnerOther
Transactions
- Award
Stock Option (right to buy)
2019-11-19+150,000→ 150,000 totalExercise: $18.74Exp: 2026-11-19→ Common Stock, par value $0.01 per share (150,000 underlying)
Footnotes (2)
- [F1]Dr. Aghazadeh was granted stock options pursuant to the Issuer's 2014 Long-Term Incentive Plan. 50,000 of the stock options vest upon the U.S. Food and Drug Administration's ("FDA") acceptance of the resubmission of the Issuer's Biologics License Application for sacituzumab govitecan for the treatment of patients with metastatic triple-negative breast cancer who have received at least two prior therapies for metastatic disease under the Prescription Drug User Fee Act (the "BLA"), and 100,000 of the stock options vest upon the Issuer's receipt of approval from the FDA for the BLA.
- [F2]Dr. Aghazadeh serves as the portfolio manager and controlling person of Avoro Capital Advisors LLC (formerly venBio Select Advisor LLC), a Delaware limited liability company (the "Investment Manager"). The filing of this statement shall not be deemed an admission that either of the Reporting Persons is the beneficial owner of the securities reported herein for purposes of Section 16 of the Securities Act of 1934, as amended, or otherwise. Each of the Reporting Persons expressly disclaims beneficial ownership of the securities reported herein except to the extent of its or his pecuniary interest therein.